Revolution doubles stock offering target to $2B following pancreatic cancer win
BioSpace
After Revolution Medicines' drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt o
pharminent
April 16, 2026 (Last updated: April 16, 2026)
BioSpace
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt o
